Volume | 64,885 |
|
|||||
News | (2) | ||||||
Day High | 1.8815 | Low High |
|||||
Day Low | 1.76 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.76 | 1.76 | 1.8815 | 1.77 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
377 | 64,885 | $ 1.83 | $ 118,565 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:29:40 | 1 | $ 1.8192 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.9M | 9.33M | - | 18k | -29.05M | -3.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.48 | 1.92 | 1.4201 | 1.64 | 122,058 | 0.335 | 22.64% |
1 Month | 1.54 | 2.00 | 1.2099 | 1.58 | 153,456 | 0.275 | 17.86% |
3 Months | 0.4831 | 2.98 | 0.4444 | 1.51 | 1,080,466 | 1.33 | 275.70% |
6 Months | 3.35 | 4.999 | 0.2619 | 1.68 | 760,377 | -1.54 | -45.82% |
1 Year | 13.90 | 16.50 | 0.2619 | 5.24 | 642,687 | -12.09 | -86.94% |
3 Years | 35.60 | 45.80 | 0.2619 | 10.48 | 413,232 | -33.79 | -94.90% |
5 Years | 75.00 | 124.30 | 0.2619 | 33.16 | 415,755 | -73.19 | -97.58% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |